New Survival Prediction Tool Outperforms TNM Staging for Laryngeal Cancer Patients

Laryngeal cancer remains one of the most formidable challenges in head and neck oncology, and now a team of researchers has unveiled a new statistical tool that could change how clinicians forecast the fate of patients diagnosed with the disease. In a study published in Clinical Cancer Bulletin, Hong-Lu Zhou and Dan-Dan Chen of the Shanghai Institute of Biological Products constructed and validated a nomogram—a graphical calculating device that translates complex statistical models into a simple point-based chart—capable of predicting cancer-specific survival in patients with laryngeal squamous cell carcinoma, the histological type that accounts for more than 95 percent of all laryngeal malignancies. Drawing on two decades of population-level data, the researchers demonstrated that their model consistently outperformed the traditional tumor-node-metastasis staging system that has long served as the backbone of prognostic assessment in oncology.

The scale of the problem the study addresses is considerable. According to the Global Cancer Statistics 2020 report, roughly 184,615 people worldwide are diagnosed with laryngeal cancer each year, and nearly 100,000 die from it annually. In China alone, projections for 2022 estimated almost 30,800 new cases and about 16,900 deaths. Despite an expanding arsenal of treatments—surgery, radiotherapy, chemotherapy, and combinations tailored to individual circumstances—the five-year overall survival rate has stubbornly hovered between 50 and 60 percent for years. That stagnation, the authors argue, reflects in part the limits of the tools clinicians use to judge prognosis. The TNM staging system, which classifies tumors by their size and local extent, lymph node involvement, and distant metastasis, performs reasonably well when applied to entire populations but falters at the level of the individual patient, where two people with ostensibly identical stage designations can experience dramatically different outcomes.

To build a more discriminating instrument, the researchers turned to the Surveillance, Epidemiology, and End Results database, a vast population-based registry maintained by the United States National Cancer Institute. From records spanning 2000 to 2020, they identified 3,866 patients aged 18 or older with confirmed laryngeal squamous cell carcinoma, applying strict inclusion criteria based on International Classification of Diseases site and histology codes and excluding patients with multiple primary tumors, missing data, diagnoses made only at autopsy, or survival times shorter than three months. The cohort was then randomly split, by computer-generated assignment, into two equal halves: a training cohort of 1,933 patients used to identify prognostic factors and construct the model, and a validation cohort of another 1,933 patients used to test whether the model’s predictions held up in independent data.

The statistical machinery behind the nomogram began with univariable Cox regression analyses, which screened each candidate variable for an association with cancer-specific survival—defined as the interval from diagnosis to death specifically attributable to laryngeal cancer. Variables passing that initial filter were then subjected to multivariable Cox regression, a technique that isolates the independent contribution of each factor while accounting for the influence of all the others. Ten variables emerged as significantly associated with survival: age, race, marital status, primary tumor site within the larynx, tumor size, histologic grade, and the T, N, and M stages of the TNM system, along with whether the patient had undergone surgery on the primary tumor. Each of these factors was assigned a weighted point value in the final nomogram, allowing a clinician to total a patient’s score and read off the estimated probability of surviving one, three, or five years.

The demographic portrait of the cohort underscores the epidemiology of the disease. The overwhelming majority of patients were men over the age of 50—91.83 percent of the sample fell into that age bracket—consistent with the male-to-female incidence ratio of roughly seven to one reported for laryngeal cancer globally. Nearly 80 percent of patients were white, and tumors arose most frequently in the supraglottis, the region above the vocal cords, which accounted for 49.46 percent of cases, followed by the glottis, the vocal cord region itself, at 37.84 percent. Most tumors were moderately differentiated, classified as Grade II, and the vast majority of patients had no lymph node involvement or distant spread at diagnosis. Where distant metastases did occur, the lung was by far the most common site, hosting 64.5 percent of such lesions. During follow-up, 851 patients died of laryngeal cancer, split almost evenly between the two cohorts, with a median survival time of 32 months overall.

The performance metrics of the finished nomogram tell a story of solid, reproducible accuracy. Harrell’s concordance index, or C-index, which measures how well a model ranks patients by risk, reached 0.709 in the training cohort and 0.734 in the validation cohort—figures indicating substantial discriminatory capability. Receiver operating characteristic analysis, which evaluates the trade-off between sensitivity and specificity, yielded area under the curve values of 0.728, 0.746, and 0.766 for one-, three-, and five-year survival predictions in the training cohort, and 0.771, 0.751, and 0.763 in the validation cohort. Calibration curves, generated through 1,000 bootstrapped resampling iterations, showed close alignment between predicted and observed survival probabilities in both cohorts, meaning the model’s confidence in its estimates was matched by real-world outcomes.

Perhaps most striking is how the nomogram fared against the entrenched TNM staging system in head-to-head comparisons. Three complementary statistical approaches all pointed in the same direction. Decision curve analysis, which quantifies the net clinical benefit of a predictive model across a range of decision thresholds, showed the nomogram delivering greater net benefit than TNM staging across a broad spectrum of threshold probabilities in both cohorts. Net reclassification improvement, which measures how many patients are correctly shifted into better or worse risk categories compared with a reference model, reached 0.205, 0.304, and 0.322 at one, three, and five years in the training cohort, and 0.163, 0.203, and 0.182 in the validation cohort. Integrated discrimination improvement, a related metric capturing gains in predictive precision, was likewise positive at every time point. Together, these results suggest the nomogram genuinely adds information that TNM staging alone cannot provide.

Beyond its predictive scores, the tool offers a practical route to risk stratification. Using X-tile software, the researchers established cutoff values of 146 and 247 total points, dividing patients into low-, intermediate-, and high-risk groups. Kaplan-Meier survival curves, analyzed with the log-rank test, revealed starkly divergent survival trajectories among the three strata in both cohorts, with high-risk patients experiencing significantly worse cancer-specific survival. In effect, the nomogram converts a scatter of individual clinical details into a single number that sorts patients into clinically meaningful risk tiers—a capability that could guide decisions about treatment intensity and follow-up frequency for individual patients rather than average ones.

The study’s findings on individual prognostic factors echo and extend earlier research. Older age carried a steeply rising mortality risk, with hazard ratios of 1.82, 2.01, and 3.57 for patients aged 50 to 59, 60 to 69, and 70 and above, respectively, compared with younger patients—a pattern the authors attribute to the cumulative accumulation of environmental exposures over a lifetime and to age-related changes in laryngeal tissue. Black patients faced a significantly elevated risk of death, with a hazard ratio of 1.47, a disparity the researchers link to a complex interplay of genetic predisposition, socioeconomic factors, unequal access to screening and treatment, and differences in health behaviors and environmental exposures. Notably, male sex, often reported as a risk factor in prior studies, did not reach statistical significance here, with a hazard ratio of 1.22 and a P-value of 0.1050—a discrepancy the authors suggest may stem from the limited number of female patients in the cohort.

The authors are candid about the limitations that temper their conclusions. The model was built exclusively on retrospective data from the American population, and the researchers caution that it is not yet mature enough for direct application in Chinese patients given ethnic differences. Crucially, some of the most important risk factors for laryngeal cancer—smoking habits, alcohol consumption, and human papillomavirus infection—could not be incorporated because the SEER database does not capture them, leaving open the possibility that the model’s accuracy could improve further with richer inputs. Prospective data collection, larger and more geographically diverse cohorts, and external validation across different populations remain essential next steps. Still, the study represents a meaningful advance: a convenient, practical, and well-calibrated tool that gives clinicians a sharper lens on individual prognosis at a time when the survival outlook for laryngeal cancer patients has barely moved in decades. For a disease that strikes hardest at older men and disproportionately burdens disadvantaged communities, a better way to see who is truly at risk may be the first step toward changing the numbers themselves.

Subject of Research: Development of a nomogram for predicting cancer-specific survival in laryngeal squamous cell carcinoma using SEER database data

Article Title: A nomogram for predicting cancer-specific survival in patients with laryngeal squamous cell carcinoma: a population-based study from SEER database

Article References: Zhou, H.-L., & Chen, D.-D. (2025). A nomogram for predicting cancer-specific survival in patients with laryngeal squamous cell carcinoma: a population-based study from SEER database. Clinical Cancer Bulletin, 4(1), Article 8. https://doi.org/10.1007/s44272-025-00037-z

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00037-z

Keywords: laryngeal squamous cell carcinoma, nomogram, cancer-specific survival, SEER database, TNM staging, prognostic factors, Cox regression, risk stratification, head and neck cancer, decision curve analysis, C-index, survival prediction